{"id":7518,"date":"2024-04-17T09:56:30","date_gmt":"2024-04-17T09:56:30","guid":{"rendered":"https:\/\/ambercell.eu\/?p=7518"},"modified":"2024-06-27T14:34:29","modified_gmt":"2024-06-27T14:34:29","slug":"tika-veikta-pirma-aknu-audzeja-elektrokimiska-terapija-izmantojot-cas-one-ir","status":"publish","type":"post","link":"https:\/\/ambercell.eu\/lv\/zinas\/tika-veikta-pirma-aknu-audzeja-elektrokimiska-terapija-izmantojot-cas-one-ir\/","title":{"rendered":"Transarerisk\u0101 \u0137\u012bmijemboliz\u0101cija (TACE) \u2013 efekt\u012bvs l\u012bdzeklis c\u012b\u0146\u0101 pret aknu v\u0113zi"},"content":{"rendered":"\n

Gan Eirop\u0101, gan vis\u0101 pasaul\u0113 pieaug aknu v\u0113\u017ea gad\u012bjumu skaits. No aknu onkolo\u0123iskaj\u0101m slim\u012bb\u0101m visbie\u017e\u0101k sastopam\u0101s ir aknu \u0161\u016bnu hepatocelul\u0101r\u0101 karcinoma pieaugu\u0161ajiem (prim\u0101rais aknu audz\u0113js), holangiokarcinoma (prim\u0101rais aknu \u017eultsvadu audz\u0113js), k\u0101 ar\u012b sekund\u0101rie audz\u0113ji \u2013 da\u017e\u0101du aknu audz\u0113ju metast\u0101zes akn\u0101s. Hepatocelul\u0101r\u0101 karcinoma (HCC) veido aptuveni 75-80 procentus. aknu v\u0113\u017ea gad\u012bjumi. Tas ir visizplat\u012bt\u0101kais prim\u0101rais aknu audz\u0113js, kas ie\u0146em piekto vietu starp onkolo\u0123iskaj\u0101m slim\u012bb\u0101m pasaul\u0113 un otro vietu p\u0113c t\u0101 izrais\u012bto n\u0101ves gad\u012bjumu skaita. Pasaul\u0113 gad\u0101 tiek atkl\u0101ti aptuveni 854 000 jaunu gad\u012bjumu, kas veido pat 7 procentus no visiem audz\u0113jiem. Katru gadu no \u0161\u012bs slim\u012bbas mirst aptuveni 810 000 cilv\u0113ku. Eirop\u0101 hepatocelul\u0101r\u0101s karcinomas sastopam\u012bbas un mirst\u012bbas r\u0101d\u012bt\u0101ji pieaugu\u0161ajiem ir attiec\u012bgi 65000 un 60240 gad\u012bjumi. Par \u0161o draudo\u0161o slim\u012bbu un inovat\u012bvaj\u0101m \u0101rst\u0113\u0161anas iesp\u0113j\u0101m, kas respekt\u0113 pacientu vesel\u012bbu ,<\/a> onkolo\u0123e \u0137\u012bmijterapeite Vaida Gedaminien\u0117 un Invaz\u012bv\u0101s radiolo\u0123ijas noda\u013cas vad\u012bt\u0101ja, \u0101rste invaz\u012bv\u0101 radiolo\u0123e Algimantas \u0160imkaitis st\u0101sta par \u0161o draudo\u0161o slim\u012bbu un inovat\u012bv\u0101m \u0101rst\u0113\u0161anas iesp\u0113j\u0101m, kas respekt\u0113 pacientu vesel\u012bbu.<\/p>\n\n

Slim\u012bba, ko izraisa hroniskas aknu slim\u012bbas, vairum\u0101 gad\u012bjumu tiek diagnostic\u0113ta progres\u012bv\u0101s stadij\u0101s<\/strong><\/p>\n\n

P\u0113c V. Gedaminien\u0117 dom\u0101m, hepatocelul\u0101r\u0101 karcinoma pieaugu\u0161ajiem ir \u0101rk\u0101rt\u012bgi agres\u012bvs v\u0113\u017ea veids, kura \u0101rst\u0113\u0161anas iesp\u0113jas ir ierobe\u017eotas. Tas ir viens no svar\u012bg\u0101kajiem v\u0113\u017ea n\u0101ves c\u0113lo\u0146iem vis\u0101 pasaul\u0113. M\u016bsu valst\u012b katru gadu tiek diagnostic\u0113ti aptuveni 190 jauni HCC gad\u012bjumi, no kuriem aptuveni 40 – III-IV posmi. Visbie\u017e\u0101k \u0161\u012b slim\u012bba tiek atkl\u0101ta person\u0101m vecum\u0101 no 50 l\u012bdz 70 gadiem.<\/p>\n\n

P\u0113c onkologa \u0137\u012bmijterapeita dom\u0101m, aknu \u0161\u016bnu hepatocelul\u0101r\u0101 karcinoma pieaugu\u0161ajiem visbie\u017e\u0101k att\u012bst\u0101s pacientiem ar aknu cirozi, ko izraisa hronisks v\u012brusu hepat\u012bts C vai B, alkohola lieto\u0161ana, retas aknu slim\u012bbas, aptauko\u0161an\u0101s. \u0160\u012b onkolo\u0123isk\u0101 slim\u012bba att\u012bst\u0101s no hepatoc\u012btiem un bie\u017ei ir saist\u012bta ar hronisk\u0101m aknu slim\u012bb\u0101m. Slim\u012bbas s\u0101kum\u0101 att\u012bst\u0101s aknu iekaisums, ko var izrais\u012bt C un B hepat\u012bta v\u012brusu infekcija, alkohola lieto\u0161ana, aptauko\u0161an\u0101s, retas aknu slim\u012bbas. P\u0113c tam iekaisuma izmai\u0146as progres\u0113 fibroz\u0113 un ciroz\u0113, kas var p\u0101rveidoties par pieaugu\u0161o hepatocelul\u0101ro karcinomu. Parasti \u0161\u012b slim\u012bba tiek diagnostic\u0113ta jau progres\u012bvos posmos. Prognoze neoper\u0113tiem pacientiem ar pieaugu\u0161o hepatocelul\u0101ro karcinomu joproj\u0101m ir slikta \u2013 viena gada izdz\u012bvo\u0161anas r\u0101d\u012bt\u0101js no diagnozes s\u0101kuma ir maz\u0101ks par 50 procentiem.<\/p>\n\n

V. Gedaminien\u0117 saka, ka pieaugu\u0161o pacientu s\u016bdz\u012bbas ar hepatocelul\u0101ro karcinomu nav specifiskas: nogurums, v\u0101jums, apet\u012btes tr\u016bkums, svara zudums, s\u0101pes v\u0113dera aug\u0161da\u013c\u0101, nepieredz\u0113jis veidojums v\u0113dera aug\u0161da\u013c\u0101, nezin\u0101mas izcelsmes drudzis, slikta d\u016b\u0161a, palielin\u0101ts v\u0113dera tilpums, dzelte. Visbie\u017e\u0101k \u0161ie simptomi par\u0101d\u0101s jau progres\u0113jo\u0161as slim\u012bbas kl\u0101tb\u016btn\u0113.<\/p>\n\n

Lai p\u0113c iesp\u0113jas \u0101tr\u0101k atkl\u0101tu HCC, pacientiem ar aknu cirozi ieteicams veikt aknu ultraska\u0146as sken\u0113\u0161anu ik p\u0113c 6 m\u0113ne\u0161iem un p\u0101rbaud\u012bt v\u0113\u017ea mar\u0137iera alfafetoprote\u012bna (AFP) koncentr\u0101ciju asin\u012bs. Ja ir aizdomas par slim\u012bbu, tiek izmantotas citas radiolo\u0123isk\u0101s metodes \u2013 datortomogr\u0101fija (CT), magn\u0113tisk\u0101s rezonanses att\u0113lveido\u0161ana (MRI), tiek veikta biopsija un mikroskopiski izmekl\u0113ta da\u013ca aknu audu.<\/p>\n\n

Hepatocelul\u0101r\u0101s karcinomas \u0101rst\u0113\u0161anas taktiku izv\u0113las multidisciplin\u0101ra komanda<\/strong><\/p>\n\n

P\u0113c onkologa \u0137\u012bmijterapeita dom\u0101m, katra pacienta \u0101rst\u0113\u0161ana ar HCC KUL tiek pl\u0101nota individu\u0101li, katr\u0101 gad\u012bjum\u0101 izv\u0113loties optim\u0101lo \u0101rst\u0113\u0161anas metodi vai to sec\u012bbu. \u0100rst\u0113\u0161ana pl\u0101nota multidisciplin\u0101ras komandas diskusijas laik\u0101, kur piedal\u0101s \u0137irurgs, radiologs, invaz\u012bvais radiologs, onkologs \u0137\u012bmijterapeits un onkologs radioterapeits. Izv\u0113loties \u0101rst\u0113\u0161anu, speci\u0101listi \u0146em v\u0113r\u0101 daudzus faktorus \u2013 pacienta vecumu, visp\u0101r\u0113jo vesel\u012bbas st\u0101vokli, audz\u0113ja lielumu, veidu un izplat\u012bbu, citas svar\u012bgas slim\u012bbas, ar kur\u0101m pacients slimo. Izv\u0113rt\u0113jot visus tos, \u0101rsti izv\u0113las \u0101rst\u0113\u0161anas taktiku. Jo agr\u0101k tiek atkl\u0101ts HCC posms, jo radik\u0101l\u0101ku \u0101rst\u0113\u0161anu var piem\u0113rot. Aknu rezekcija vai aknu transplant\u0101cija tiek veikta, kad tiek atkl\u0101ta slim\u012bbas agr\u012bn\u0101 stadija. Ja \u0137irur\u0123iska \u0101rst\u0113\u0161ana nav iesp\u0113jama, tiek izv\u0113rt\u0113ta radiofrekvences abl\u0101cijas vai transarterisk\u0101s \u0137\u012bmijterapijas (TACE)<\/a> iesp\u0113jam\u012bba.<\/p>\n\n

<\/div>\n\n
\n
\"\"<\/figure>\n<\/figure>\n\n
<\/div>\n\n

V. Gedaminien\u0117 st\u0101sta, ka progres\u0113jo\u0161a hepatocelul\u0101ra karcinoma Lietuv\u0101 tiek \u0101rst\u0113ta ar noteiktu medikamentu (Atezolizumaba un Bevacizumaba) kombin\u0101ciju. P\u0113c speci\u0101lista teikt\u0101, \u0161\u012b ir pirm\u0101 un vien\u012bg\u0101 Eirop\u0101 re\u0123istr\u0113t\u0101 v\u0113\u017ea im\u016bnterapijas sh\u0113ma, kas nedarbojas HCC pacientu \u0101rst\u0113\u0161anai. \u0160\u012b kombin\u0101cija uzlabo kop\u0113jo dz\u012bvildzi un dz\u012bvildzi bez slim\u012bbas progres\u0113\u0161anas, sal\u012bdzinot ar iepriek\u0161\u0113jo parasto \u0101rst\u0113\u0161anu. Athezolizumab un Bevacizumab kombin\u0101cija ir iek\u013cauta Eiropas Onkolo\u0123ijas biedr\u012bbas ieteikumos un daudz\u0101s cit\u0101s kl\u012bnisk\u0101s prakses vadl\u012bnij\u0101s neoper\u0113jamu HCC pacientu \u0101rst\u0113\u0161anai.<\/p>\n\n

Saska\u0146\u0101 ar p\u0113t\u012bjuma rezult\u0101tiem, kas par\u0101d\u012bja, ka iepriek\u0161 min\u0113to z\u0101\u013cu kombin\u0101cija samazin\u0101ja n\u0101ves risku \u2013 kop\u0113j\u0101s dz\u012bvildzes (BI) r\u0101d\u012bjums palielin\u0101j\u0101s par 42%, k\u0101 ar\u012b slim\u012bbas progres\u0113\u0161anas vai n\u0101ves risks \u2013 izdz\u012bvo\u0161anas bez slim\u012bbas progres\u0113\u0161anas (PFS) r\u0101d\u012bt\u0101js palielin\u0101j\u0101s par 41%, sal\u012bdzinot ar sorafeniba iedarb\u012bbu,” st\u0101sta onkologs \u0137\u012bmijterapeits.<\/p>\n\n

Aknu v\u0113\u017ea \u0101rst\u0113\u0161anas strat\u0113\u0123ij\u0101s veiksm\u012bgi tiek izveidota transararisk\u0101 \u0137\u012bmijemboliz\u0101cija<\/strong><\/p>\n\n

<\/a>Viena no visbie\u017e\u0101k izmantotaj\u0101m intervences onkoradiolo\u0123ijas \u0101rst\u0113\u0161anas metod\u0113m ir trans-art\u0113risk\u0101 \u0137\u012bmijemboliz\u0101cija (TACE).<\/p>\n\n

Saska\u0146\u0101 ar Algimantas \u0160imkaitis, TACE daudzos aspektos izce\u013cas no cit\u0101m \u0101rst\u0113\u0161anas metod\u0113m. Viena no \u0161\u012bs metodes priek\u0161roc\u012bb\u0101m sal\u012bdzin\u0101jum\u0101 ar audz\u0113ja \u0137irur\u0123isku \u0101rst\u0113\u0161anu ir t\u0101, ka proced\u016bra tiek veikta bez griezuma \u2013 caur milimetru griezumu \u0101d\u0101 tiek ievad\u012bti pl\u0101nie katetri. Nav nepiecie\u0161ama ar\u012b visp\u0101r\u0113j\u0101 anest\u0113zija (anest\u0113zija) \u2013 \u0101rst\u0113\u0161anas laik\u0101 tiek anestez\u0113ts tikai katetra ieejas punkts \u0101d\u0101. Sal\u012bdzinot ar sist\u0113misko \u0101rst\u0113\u0161anu, kad intravenozi ievad\u012bti \u0137\u012bmijterapijas l\u012bdzek\u013ci cirkul\u0113 vis\u0101 \u0137ermen\u012b, k\u0101 ar\u012b iedarbojas uz viet\u0101m, kuras audz\u0113js nav saboj\u0101jis, TACE proced\u016bras laik\u0101 ar \u0137\u012bmijprepar\u0101tiem pies\u0101tin\u0101tas da\u013ci\u0146as tiek injic\u0113tas tie\u0161i slim\u012bbas centr\u0101, t\u0101d\u0113j\u0101di iedarbojoties uz m\u0113r\u0137i augst\u0101s koncentr\u0101cij\u0101s, vienlaikus saudz\u0113jot blakus eso\u0161os audus un neapdraudot pacienta dz\u012bves kvalit\u0101ti. \u0160\u012b ir \u0101rk\u0101rt\u012bgi prec\u012bza un dro\u0161a metode, kas \u013cauj ietekm\u0113t tikai audz\u0113ju, nesaboj\u0101jot ne tikai citus org\u0101nus, bet ar\u012b vesel\u012bgu aknu da\u013cu. Turkl\u0101t z\u0101les, kas uzs\u016bcas uz mikrosf\u0113ru virsmas, iedarbojas uz iekaisu\u0161ajiem aknu audiem iev\u0113rojami ilg\u0101k nek\u0101 ar cit\u0101m \u0101rst\u0113\u0161anas metod\u0113m.<\/p>\n\n

<\/div>\n\n
\"\"<\/figure>\n\n
<\/div>\n\n

“Tom\u0113r, t\u0101pat k\u0101 daudz\u0101m cit\u0101m onkolo\u0123isk\u0101s slim\u012bbas \u0101rst\u0113\u0161anas metod\u0113m (\u0137irur\u0123ija, abl\u0101cija, sistem\u0101tiskas \u0101rst\u0113\u0161anas metodes, apstaro\u0161ana), trans-artoriskajai \u0137\u012bmijemboliz\u0101cijai ir tikai noteikta vieta \u0101rst\u0113\u0161anas algoritmos – \u0101rst\u0113\u0161anas noteikumos, un t\u0101 tiek piem\u0113rota multidisciplin\u0101ras komandas l\u0113mumos, kur\u0101 vair\u0101ku jomu profesion\u0101\u013ci izv\u0113las optim\u0101l\u0101ko individu\u0101lo \u0101rst\u0113\u0161anas pl\u0101nu katram pacientam. Saska\u0146\u0101 ar algoritmiem TACE var izmantot, lai sagatavotu pacientu turpm\u0101kai \u0101rst\u0113\u0161anai (p\u0101rejas princips). Izmantojot \u0161o metodi, ir iesp\u0113jams samazin\u0101t audz\u0113ja apjomu, t\u0101d\u0113j\u0101di radot apst\u0101k\u013cus audz\u0113ja operat\u012bvai iz\u0146em\u0161anai vai aknu transplant\u0101cijai. TACE var izmantot ar\u012b k\u0101 neatkar\u012bgu \u0101rst\u0113\u0161anu atsevi\u0161\u0137iem neoper\u0113tiem per\u0113k\u013ciem,” invaz\u012bvais radiologs dal\u0101s ar inovat\u012bvas \u0101rst\u0113\u0161anas metodes iesp\u0113j\u0101m.<\/p>\n\n

Transarerisk\u0101 \u0137\u012bmijemboliz\u0101cija \u2013 ne tikai \u013coti efekt\u012bva, bet ar\u012b labi panesama<\/strong><\/p>\n\n

Algimantas \u0160imkaitis st\u0101sta, ka pirms TACE veik\u0161anas katr\u0101 gad\u012bjum\u0101 tiek izv\u0113l\u0113tas \u013coti smalkas da\u013ci\u0146as \u2013 mikrosf\u0113ras, kuru izm\u0113rs ir piem\u0113rots \u0161ai proced\u016brai. To izm\u0113ri var b\u016bt no 100-200 l\u012bdz 400 mikroniem. Saska\u0146\u0101 ar katru konkr\u0113to gad\u012bjumu tiek izv\u0113l\u0113ts \u0137\u012bmijterapijas prepar\u0101ts, ar kuru izv\u0113l\u0113t\u0101 izm\u0113ra un daudzuma mikrosf\u0113ras ir pies\u0101tin\u0101tas proced\u016bras dienas r\u012bt\u0101. T\u0101d\u0101 veid\u0101 \u0161\u012b narkotika augst\u0101 koncentr\u0101cij\u0101 tiek “blo\u0137\u0113ta” sagatavotaj\u0101s mikrosf\u0113r\u0101s. Pacientam ierodoties invaz\u012bv\u0101s radiolo\u0123ijas oper\u0101ciju z\u0101l\u0113, caur lok\u0101li anest\u0113zijas punktu tiek ievad\u012bti gari pl\u0101ni (~1mm diametr\u0101) katetri. Ar tiem angiogr\u0101fijas apar\u0101ta kontrol\u0113 tiek sasniegts audz\u0113js, nov\u0113rt\u0113tas t\u0101 asinsrites \u012bpatn\u012bbas, izv\u0113l\u0113ti pat pl\u0101n\u0101ki mikrokateti, caur kuriem fokus\u0101 tiek ievad\u012btas mikrosf\u0113ras, kas pies\u0101tin\u0101tas ar \u0137\u012bmijterapijas z\u0101l\u0113m, aizsarg\u0101jot veselus audus.<\/p>\n\n

Viens no TACE efektiem ir audz\u0113ja blo\u0137\u0113\u0161ana, emboliz\u0113jot t\u0101 asinsriti, izraisot t\u0101 i\u0161\u0113miju, infarktu. Otrais efekts ir z\u0101les, kas izdal\u0101s no injic\u0113taj\u0101m mikrosf\u0113r\u0101m tikai taj\u0101 boj\u0101taj\u0101 zon\u0101, iedarbojoties tikai uz audz\u0113ju augst\u0101s koncentr\u0101cij\u0101s, taj\u0101 pa\u0161\u0101 laik\u0101 to var noteikt sist\u0113miskaj\u0101 cirkul\u0101cij\u0101 tikai \u013coti zem\u0101s koncentr\u0101cij\u0101s. Svar\u012bgi ir ar\u012b tas, ka \u0101rst\u0113\u0161anu ar TACE var atk\u0101rtot un to bie\u017ei atk\u0101rto vair\u0101kas reizes. Proced\u016bras ilgums atkar\u012bb\u0101 no fokusa skaita, lieluma un anatomisk\u0101s sare\u017e\u0123\u012bt\u012bbas katr\u0101 gad\u012bjum\u0101 ir at\u0161\u0137ir\u012bgs – no 30 min\u016bt\u0113m l\u012bdz 1,5 stund\u0101m.<\/p>\n\n

P\u0113c proced\u016bras pacients tiek atgriezts noda\u013c\u0101 t\u0101l\u0101kai nov\u0113ro\u0161anai. Atsevi\u0161\u0137os gad\u012bjumos \u0101rsta pus\u0113 var par\u0101d\u012bties s\u0101p\u012bgums, pacients var justies slikti, temperat\u016bra var paaugstin\u0101ties, bet \u0161ie zin\u0101mie simptomi tiek nov\u0113roti, t\u0101p\u0113c savlaic\u012bgi tiek noteikta efekt\u012bva \u0101rst\u0113\u0161ana, kas tos nom\u0101c. Arvien izplat\u012bt\u0101k\u0101 prakse veikt TACE dienas stacion\u0101ra apst\u0101k\u013cos, un pacients tiek izvad\u012bts m\u0101j\u0101 t\u0101s pa\u0161as dienas vakar\u0101, liecina, ka proced\u016bra ir pietiekami labi panesama.<\/p>\n\n

Invaz\u012bv\u0101s radiolo\u0123ijas noda\u013cas vad\u012bt\u0101js Algimantas \u0160imkaitis st\u0101sta, ka TACE ir iesp\u0113ja cilv\u0113kam, kur\u0161 c\u012bn\u0101s ar onkolo\u0123isko slim\u012bbu, sa\u0146emt vi\u0146am piem\u0113rot\u0101ko \u0101rst\u0113\u0161anu saska\u0146\u0101 ar m\u016bsdienu \u0101rst\u0113\u0161anas vadl\u012bnij\u0101m. \u0160\u012b proced\u016bra m\u016bsu valst\u012b tiek kompens\u0113ta no oblig\u0101t\u0101s vesel\u012bbas apdro\u0161in\u0101\u0161anas bud\u017eeta. \u0100rstam onkologam, kur\u0161 vada pacientu ce\u013cojum\u0101 pa slim\u012bbu, transarter\u0101l\u0101 \u0137\u012bmijemboliz\u0101cija ir v\u0113l viens instruments vis\u0101 iesp\u0113ju palet\u0113, kas \u013cauj neierobe\u017eoti izv\u0113l\u0113ties optim\u0101l\u0101ko \u0101rst\u0113\u0161anu katram konkr\u0113tajam gad\u012bjumam, sp\u0113ju kontrol\u0113t slim\u012bbas progresu, demonstr\u0113t labus recid\u012bva un izdz\u012bvo\u0161anas r\u0101d\u012bt\u0101jus.<\/p>\n\n

“Veicot transarter\u0101lo \u0137\u012bmijterapiju KUL fili\u0101l\u0113 “Klaip\u0113das slimn\u012bca”, m\u0113s varam pied\u0101v\u0101t efekt\u012bvu \u0101rst\u0113\u0161anu ikvienam pacientam ar onkolo\u0123isko slim\u012bbu, kur\u0161 pie mums v\u0113r\u0161as bez ierun\u0101m. Invaz\u012bv\u0101s radiolo\u0123ijas centr\u0101 papildus TACE invaz\u012bvais onkoradiologs var noteikt t\u0101das terapeitiskas proced\u016bras k\u0101 fokusa (aukstuma, radiofrekvences vai mikrovi\u013c\u0146u kr\u0101sns) izn\u012bcin\u0101\u0161ana-abl\u0101cija, elektro\u0137\u012bmisk\u0101 terapija, trans-arteri\u0101l\u0101 emboliz\u0101cija bez \u0137\u012bmijterapijas (TAE). Svar\u012bgi ir ar\u012b tas, ka invaz\u012bvais radiologs ir iesaist\u012bts pat slim\u012bbas atkl\u0101\u0161anas stadij\u0101, veicot biopsiju. Sadarb\u012bb\u0101 ar radiolo\u0123ijas kl\u012bnikas onkoradiolo\u0123ijas noda\u013cas speci\u0101listiem pacientiem tiek garant\u0113ta gan agr\u012bna diagnostika, gan turpm\u0101ka izseko\u0161ana \u2013 \u0101rst\u0113\u0161anas efektivit\u0101tes monitorings,” st\u0101sta A. \u0160imkaitis. Sarunas nosl\u0113gum\u0101 \u0101rsts invaz\u012bvais radiologs st\u0101sta, ka m\u016bsdienu medic\u012bnas progresu nodro\u0161ina gan jaun\u0101kie zin\u0101tnes sasniegumi, gan jauni p\u0113t\u012bjumi, gan tehnolo\u0123iskais progress \u2013 jaun\u0101k\u0101s iek\u0101rtas, tehnolo\u0123ijas, kas katru dienu moderniz\u0113jas, tostarp m\u0101ksl\u012bg\u0101 intelekta integr\u0101cija visos posmos. M\u016bsdien\u012bg\u0101, past\u0101v\u012bgi atjaunojo\u0161\u0101 KUL fili\u0101le “Klaip\u0113das slimn\u012bca” un \u0161eit str\u0101d\u0101jo\u0161o speci\u0101listu nemit\u012bg\u0101 kvalifik\u0101cijas cel\u0161ana var garant\u0113t dro\u0161us, individualiz\u0113tus, efekt\u012bvus pakalpojumus pacientam, kur\u0161 saskaras ar jebk\u0101d\u0101m vesel\u012bbas probl\u0113m\u0101m<\/p>\n\n

<\/div>\n\n
\"\"<\/figure>\n\n
<\/div>\n","protected":false},"excerpt":{"rendered":"

Eirop\u0101 hepatocelul\u0101r\u0101s karcinomas sastopam\u012bbas un mirst\u012bbas r\u0101d\u012bt\u0101ji pieaugu\u0161ajiem ir attiec\u012bgi 65000 un 60240 gad\u012bjumi. Par \u0161o draudo\u0161o slim\u012bbu un inovat\u012bvaj\u0101m \u0101rst\u0113\u0161anas iesp\u0113j\u0101m, kas respekt\u0113 pacientu vesel\u012bbu, onkolo\u0123e \u0137\u012bmijterapeite Vaida Gedaminien\u0117 un Invaz\u012bv\u0101s radiolo\u0123ijas noda\u013cas vad\u012bt\u0101ja, \u0101rste invaz\u012bv\u0101 radiolo\u0123e Algimantas \u0160imkaitis st\u0101sta par \u0161o draudo\u0161o slim\u012bbu un inovat\u012bv\u0101m \u0101rst\u0113\u0161anas iesp\u0113j\u0101m, kas respekt\u0113 pacientu vesel\u012bbu.<\/p>\n","protected":false},"author":8,"featured_media":7556,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[38],"tags":[],"class_list":["post-7518","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-zinas"],"yoast_head":"\nTransarerisk\u0101 \u0137\u012bmijemboliz\u0101cija (TACE) \u2013 efekt\u012bvs l\u012bdzeklis c\u012b\u0146\u0101 pret aknu v\u0113zi - Ambercell<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ambercell.eu\/lv\/zinas\/tika-veikta-pirma-aknu-audzeja-elektrokimiska-terapija-izmantojot-cas-one-ir\/\" \/>\n<meta property=\"og:locale\" content=\"lv_LV\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Transarerisk\u0101 \u0137\u012bmijemboliz\u0101cija (TACE) \u2013 efekt\u012bvs l\u012bdzeklis c\u012b\u0146\u0101 pret aknu v\u0113zi - Ambercell\" \/>\n<meta property=\"og:description\" content=\"Eirop\u0101 hepatocelul\u0101r\u0101s karcinomas sastopam\u012bbas un mirst\u012bbas r\u0101d\u012bt\u0101ji pieaugu\u0161ajiem ir attiec\u012bgi 65000 un 60240 gad\u012bjumi. Par \u0161o draudo\u0161o slim\u012bbu un inovat\u012bvaj\u0101m \u0101rst\u0113\u0161anas iesp\u0113j\u0101m, kas respekt\u0113 pacientu vesel\u012bbu, onkolo\u0123e \u0137\u012bmijterapeite Vaida Gedaminien\u0117 un Invaz\u012bv\u0101s radiolo\u0123ijas noda\u013cas vad\u012bt\u0101ja, \u0101rste invaz\u012bv\u0101 radiolo\u0123e Algimantas \u0160imkaitis st\u0101sta par \u0161o draudo\u0161o slim\u012bbu un inovat\u012bv\u0101m \u0101rst\u0113\u0161anas iesp\u0113j\u0101m, kas respekt\u0113 pacientu vesel\u012bbu.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ambercell.eu\/lv\/zinas\/tika-veikta-pirma-aknu-audzeja-elektrokimiska-terapija-izmantojot-cas-one-ir\/\" \/>\n<meta property=\"og:site_name\" content=\"Ambercell\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-17T09:56:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-06-27T14:34:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ambercell.eu\/wp-content\/uploads\/2024\/04\/Gydytojas-Algimantas-Simkaitis-1024x689.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"689\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"rg_digitally\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"rg_digitally\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"11 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ambercell.eu\\\/lv\\\/zinas\\\/tika-veikta-pirma-aknu-audzeja-elektrokimiska-terapija-izmantojot-cas-one-ir\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ambercell.eu\\\/lv\\\/zinas\\\/tika-veikta-pirma-aknu-audzeja-elektrokimiska-terapija-izmantojot-cas-one-ir\\\/\"},\"author\":{\"name\":\"rg_digitally\",\"@id\":\"https:\\\/\\\/ambercell.eu\\\/#\\\/schema\\\/person\\\/de1118b7d1a3e64a0961221f4f9f928e\"},\"headline\":\"Transarerisk\u0101 \u0137\u012bmijemboliz\u0101cija (TACE) \u2013 efekt\u012bvs l\u012bdzeklis c\u012b\u0146\u0101 pret aknu v\u0113zi\",\"datePublished\":\"2024-04-17T09:56:30+00:00\",\"dateModified\":\"2024-06-27T14:34:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ambercell.eu\\\/lv\\\/zinas\\\/tika-veikta-pirma-aknu-audzeja-elektrokimiska-terapija-izmantojot-cas-one-ir\\\/\"},\"wordCount\":2129,\"publisher\":{\"@id\":\"https:\\\/\\\/ambercell.eu\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/ambercell.eu\\\/lv\\\/zinas\\\/tika-veikta-pirma-aknu-audzeja-elektrokimiska-terapija-izmantojot-cas-one-ir\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ambercell.eu\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/Gydytojas-Algimantas-Simkaitis.webp\",\"articleSection\":[\"Zi\u0146as\"],\"inLanguage\":\"lv-LV\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ambercell.eu\\\/lv\\\/zinas\\\/tika-veikta-pirma-aknu-audzeja-elektrokimiska-terapija-izmantojot-cas-one-ir\\\/\",\"url\":\"https:\\\/\\\/ambercell.eu\\\/lv\\\/zinas\\\/tika-veikta-pirma-aknu-audzeja-elektrokimiska-terapija-izmantojot-cas-one-ir\\\/\",\"name\":\"Transarerisk\u0101 \u0137\u012bmijemboliz\u0101cija (TACE) \u2013 efekt\u012bvs l\u012bdzeklis c\u012b\u0146\u0101 pret aknu v\u0113zi - Ambercell\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ambercell.eu\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ambercell.eu\\\/lv\\\/zinas\\\/tika-veikta-pirma-aknu-audzeja-elektrokimiska-terapija-izmantojot-cas-one-ir\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ambercell.eu\\\/lv\\\/zinas\\\/tika-veikta-pirma-aknu-audzeja-elektrokimiska-terapija-izmantojot-cas-one-ir\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ambercell.eu\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/Gydytojas-Algimantas-Simkaitis.webp\",\"datePublished\":\"2024-04-17T09:56:30+00:00\",\"dateModified\":\"2024-06-27T14:34:29+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ambercell.eu\\\/lv\\\/zinas\\\/tika-veikta-pirma-aknu-audzeja-elektrokimiska-terapija-izmantojot-cas-one-ir\\\/#breadcrumb\"},\"inLanguage\":\"lv-LV\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ambercell.eu\\\/lv\\\/zinas\\\/tika-veikta-pirma-aknu-audzeja-elektrokimiska-terapija-izmantojot-cas-one-ir\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"lv-LV\",\"@id\":\"https:\\\/\\\/ambercell.eu\\\/lv\\\/zinas\\\/tika-veikta-pirma-aknu-audzeja-elektrokimiska-terapija-izmantojot-cas-one-ir\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ambercell.eu\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/Gydytojas-Algimantas-Simkaitis.webp\",\"contentUrl\":\"https:\\\/\\\/ambercell.eu\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/Gydytojas-Algimantas-Simkaitis.webp\",\"width\":1815,\"height\":1221},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ambercell.eu\\\/lv\\\/zinas\\\/tika-veikta-pirma-aknu-audzeja-elektrokimiska-terapija-izmantojot-cas-one-ir\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/ambercell.eu\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Transarerisk\u0101 \u0137\u012bmijemboliz\u0101cija (TACE) \u2013 efekt\u012bvs l\u012bdzeklis c\u012b\u0146\u0101 pret aknu v\u0113zi\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ambercell.eu\\\/#website\",\"url\":\"https:\\\/\\\/ambercell.eu\\\/\",\"name\":\"Ambercell\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/ambercell.eu\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ambercell.eu\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"lv-LV\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/ambercell.eu\\\/#organization\",\"name\":\"Ambercell\",\"url\":\"https:\\\/\\\/ambercell.eu\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"lv-LV\",\"@id\":\"https:\\\/\\\/ambercell.eu\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/ambercell.eu\\\/wp-content\\\/uploads\\\/2023\\\/11\\\/Ambercell-LOGO-@2x.webp\",\"contentUrl\":\"https:\\\/\\\/ambercell.eu\\\/wp-content\\\/uploads\\\/2023\\\/11\\\/Ambercell-LOGO-@2x.webp\",\"width\":438,\"height\":164,\"caption\":\"Ambercell\"},\"image\":{\"@id\":\"https:\\\/\\\/ambercell.eu\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ambercell.eu\\\/#\\\/schema\\\/person\\\/de1118b7d1a3e64a0961221f4f9f928e\",\"name\":\"rg_digitally\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"lv-LV\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/373c9d1ad005968662f61df71c524a97d5de18eafdff3ca7f42bb4d42ad37ec6?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/373c9d1ad005968662f61df71c524a97d5de18eafdff3ca7f42bb4d42ad37ec6?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/373c9d1ad005968662f61df71c524a97d5de18eafdff3ca7f42bb4d42ad37ec6?s=96&d=mm&r=g\",\"caption\":\"rg_digitally\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Transarerisk\u0101 \u0137\u012bmijemboliz\u0101cija (TACE) \u2013 efekt\u012bvs l\u012bdzeklis c\u012b\u0146\u0101 pret aknu v\u0113zi - Ambercell","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ambercell.eu\/lv\/zinas\/tika-veikta-pirma-aknu-audzeja-elektrokimiska-terapija-izmantojot-cas-one-ir\/","og_locale":"lv_LV","og_type":"article","og_title":"Transarerisk\u0101 \u0137\u012bmijemboliz\u0101cija (TACE) \u2013 efekt\u012bvs l\u012bdzeklis c\u012b\u0146\u0101 pret aknu v\u0113zi - Ambercell","og_description":"Eirop\u0101 hepatocelul\u0101r\u0101s karcinomas sastopam\u012bbas un mirst\u012bbas r\u0101d\u012bt\u0101ji pieaugu\u0161ajiem ir attiec\u012bgi 65000 un 60240 gad\u012bjumi. Par \u0161o draudo\u0161o slim\u012bbu un inovat\u012bvaj\u0101m \u0101rst\u0113\u0161anas iesp\u0113j\u0101m, kas respekt\u0113 pacientu vesel\u012bbu, onkolo\u0123e \u0137\u012bmijterapeite Vaida Gedaminien\u0117 un Invaz\u012bv\u0101s radiolo\u0123ijas noda\u013cas vad\u012bt\u0101ja, \u0101rste invaz\u012bv\u0101 radiolo\u0123e Algimantas \u0160imkaitis st\u0101sta par \u0161o draudo\u0161o slim\u012bbu un inovat\u012bv\u0101m \u0101rst\u0113\u0161anas iesp\u0113j\u0101m, kas respekt\u0113 pacientu vesel\u012bbu.","og_url":"https:\/\/ambercell.eu\/lv\/zinas\/tika-veikta-pirma-aknu-audzeja-elektrokimiska-terapija-izmantojot-cas-one-ir\/","og_site_name":"Ambercell","article_published_time":"2024-04-17T09:56:30+00:00","article_modified_time":"2024-06-27T14:34:29+00:00","og_image":[{"width":1024,"height":689,"url":"https:\/\/ambercell.eu\/wp-content\/uploads\/2024\/04\/Gydytojas-Algimantas-Simkaitis-1024x689.png","type":"image\/png"}],"author":"rg_digitally","twitter_card":"summary_large_image","twitter_misc":{"Written by":"rg_digitally","Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ambercell.eu\/lv\/zinas\/tika-veikta-pirma-aknu-audzeja-elektrokimiska-terapija-izmantojot-cas-one-ir\/#article","isPartOf":{"@id":"https:\/\/ambercell.eu\/lv\/zinas\/tika-veikta-pirma-aknu-audzeja-elektrokimiska-terapija-izmantojot-cas-one-ir\/"},"author":{"name":"rg_digitally","@id":"https:\/\/ambercell.eu\/#\/schema\/person\/de1118b7d1a3e64a0961221f4f9f928e"},"headline":"Transarerisk\u0101 \u0137\u012bmijemboliz\u0101cija (TACE) \u2013 efekt\u012bvs l\u012bdzeklis c\u012b\u0146\u0101 pret aknu v\u0113zi","datePublished":"2024-04-17T09:56:30+00:00","dateModified":"2024-06-27T14:34:29+00:00","mainEntityOfPage":{"@id":"https:\/\/ambercell.eu\/lv\/zinas\/tika-veikta-pirma-aknu-audzeja-elektrokimiska-terapija-izmantojot-cas-one-ir\/"},"wordCount":2129,"publisher":{"@id":"https:\/\/ambercell.eu\/#organization"},"image":{"@id":"https:\/\/ambercell.eu\/lv\/zinas\/tika-veikta-pirma-aknu-audzeja-elektrokimiska-terapija-izmantojot-cas-one-ir\/#primaryimage"},"thumbnailUrl":"https:\/\/ambercell.eu\/wp-content\/uploads\/2024\/04\/Gydytojas-Algimantas-Simkaitis.webp","articleSection":["Zi\u0146as"],"inLanguage":"lv-LV"},{"@type":"WebPage","@id":"https:\/\/ambercell.eu\/lv\/zinas\/tika-veikta-pirma-aknu-audzeja-elektrokimiska-terapija-izmantojot-cas-one-ir\/","url":"https:\/\/ambercell.eu\/lv\/zinas\/tika-veikta-pirma-aknu-audzeja-elektrokimiska-terapija-izmantojot-cas-one-ir\/","name":"Transarerisk\u0101 \u0137\u012bmijemboliz\u0101cija (TACE) \u2013 efekt\u012bvs l\u012bdzeklis c\u012b\u0146\u0101 pret aknu v\u0113zi - Ambercell","isPartOf":{"@id":"https:\/\/ambercell.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ambercell.eu\/lv\/zinas\/tika-veikta-pirma-aknu-audzeja-elektrokimiska-terapija-izmantojot-cas-one-ir\/#primaryimage"},"image":{"@id":"https:\/\/ambercell.eu\/lv\/zinas\/tika-veikta-pirma-aknu-audzeja-elektrokimiska-terapija-izmantojot-cas-one-ir\/#primaryimage"},"thumbnailUrl":"https:\/\/ambercell.eu\/wp-content\/uploads\/2024\/04\/Gydytojas-Algimantas-Simkaitis.webp","datePublished":"2024-04-17T09:56:30+00:00","dateModified":"2024-06-27T14:34:29+00:00","breadcrumb":{"@id":"https:\/\/ambercell.eu\/lv\/zinas\/tika-veikta-pirma-aknu-audzeja-elektrokimiska-terapija-izmantojot-cas-one-ir\/#breadcrumb"},"inLanguage":"lv-LV","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ambercell.eu\/lv\/zinas\/tika-veikta-pirma-aknu-audzeja-elektrokimiska-terapija-izmantojot-cas-one-ir\/"]}]},{"@type":"ImageObject","inLanguage":"lv-LV","@id":"https:\/\/ambercell.eu\/lv\/zinas\/tika-veikta-pirma-aknu-audzeja-elektrokimiska-terapija-izmantojot-cas-one-ir\/#primaryimage","url":"https:\/\/ambercell.eu\/wp-content\/uploads\/2024\/04\/Gydytojas-Algimantas-Simkaitis.webp","contentUrl":"https:\/\/ambercell.eu\/wp-content\/uploads\/2024\/04\/Gydytojas-Algimantas-Simkaitis.webp","width":1815,"height":1221},{"@type":"BreadcrumbList","@id":"https:\/\/ambercell.eu\/lv\/zinas\/tika-veikta-pirma-aknu-audzeja-elektrokimiska-terapija-izmantojot-cas-one-ir\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ambercell.eu\/"},{"@type":"ListItem","position":2,"name":"Transarerisk\u0101 \u0137\u012bmijemboliz\u0101cija (TACE) \u2013 efekt\u012bvs l\u012bdzeklis c\u012b\u0146\u0101 pret aknu v\u0113zi"}]},{"@type":"WebSite","@id":"https:\/\/ambercell.eu\/#website","url":"https:\/\/ambercell.eu\/","name":"Ambercell","description":"","publisher":{"@id":"https:\/\/ambercell.eu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ambercell.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"lv-LV"},{"@type":"Organization","@id":"https:\/\/ambercell.eu\/#organization","name":"Ambercell","url":"https:\/\/ambercell.eu\/","logo":{"@type":"ImageObject","inLanguage":"lv-LV","@id":"https:\/\/ambercell.eu\/#\/schema\/logo\/image\/","url":"https:\/\/ambercell.eu\/wp-content\/uploads\/2023\/11\/Ambercell-LOGO-@2x.webp","contentUrl":"https:\/\/ambercell.eu\/wp-content\/uploads\/2023\/11\/Ambercell-LOGO-@2x.webp","width":438,"height":164,"caption":"Ambercell"},"image":{"@id":"https:\/\/ambercell.eu\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ambercell.eu\/#\/schema\/person\/de1118b7d1a3e64a0961221f4f9f928e","name":"rg_digitally","image":{"@type":"ImageObject","inLanguage":"lv-LV","@id":"https:\/\/secure.gravatar.com\/avatar\/373c9d1ad005968662f61df71c524a97d5de18eafdff3ca7f42bb4d42ad37ec6?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/373c9d1ad005968662f61df71c524a97d5de18eafdff3ca7f42bb4d42ad37ec6?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/373c9d1ad005968662f61df71c524a97d5de18eafdff3ca7f42bb4d42ad37ec6?s=96&d=mm&r=g","caption":"rg_digitally"}}]}},"_links":{"self":[{"href":"https:\/\/ambercell.eu\/lv\/wp-json\/wp\/v2\/posts\/7518","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ambercell.eu\/lv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ambercell.eu\/lv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ambercell.eu\/lv\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/ambercell.eu\/lv\/wp-json\/wp\/v2\/comments?post=7518"}],"version-history":[{"count":3,"href":"https:\/\/ambercell.eu\/lv\/wp-json\/wp\/v2\/posts\/7518\/revisions"}],"predecessor-version":[{"id":8283,"href":"https:\/\/ambercell.eu\/lv\/wp-json\/wp\/v2\/posts\/7518\/revisions\/8283"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ambercell.eu\/lv\/wp-json\/wp\/v2\/media\/7556"}],"wp:attachment":[{"href":"https:\/\/ambercell.eu\/lv\/wp-json\/wp\/v2\/media?parent=7518"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ambercell.eu\/lv\/wp-json\/wp\/v2\/categories?post=7518"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ambercell.eu\/lv\/wp-json\/wp\/v2\/tags?post=7518"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}